CMPX · Compass Therapeutics, Inc.
Market Cap
$437.61M
Shares
180.09M
CMPX metrics
53 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$2.43
Market cap
$437.61M
Price action
19 metricsPrice change (1W)
+0.0%
Price change (30D)
+22.7%
Price change (3M)
+15.7%
Price change (6M)
-57.3%
Price change (YTD)
-54.7%
Price change (1Y)
-29.2%
Trailing year
Price change (5Y)
-30.6%
52-week high
$6.69
52-week low
$1.67
Change from 52-week high
-63.7%
Change from 52-week low
+45.5%
Annualized volatility
89.5%
Beta
1.3
RSI (14D)
56.4
Price vs SMA 50
+10.3%
Price vs SMA 200
-39.3%
Avg volume (3M)
3.02M
Relative volume
0.8
Average dollar volume
$6.50M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
180.09M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.6
reciprocal yield 37.9%
FCF yield
-12.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-20
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$81.08M
Net income (TTM)
−$73.45M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+30.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-44.2%
Return on assets
-38.6%
Debt / equity
—
Current ratio
11.2
EBITDA (TTM)
−$81.01M
Free cash flow (TTM)
−$56.38M
Quick ratio
11.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$35.45M
Total assets
$190.17M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$56.11M
Capital expenditures (TTM)
$265,000
R&D (TTM)
$59.47M
SG&A (TTM)
—
Stock compensation (TTM)
$12.96M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
216
13F filer change QoQ
+19
Institutional ownership
92.2%
Short interest
3 metricsShort interest
22.3%
Latest settlement · 9.8 days to cover
Days to cover
9.8d
Short-squeeze score
80 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—